News

As part of the deal, both the firms will evaluate the efficacy of combining somatostatin analogs’ neuroendocrine tumor targeting capabilities with the cell-killing potential of Areva Med’s lead-212

The collaboration also aligns with Genzyme’s early-stage MS research programs involving neuroprotection and CNS repair. The neurodegeneration observed in MS is not directly targeted by currently available treatments

Namzaric is a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor). Last December, the US Food and Drug Administration

The new Swedish facility will supply medicines for clinical trial programs of AstraZeneca and its R&D arm MedImmune from end of 2018 and will deliver finished products for

The transaction is expected to close in early June, 2015, subject to customary closing conditions. Strategic benefits of the acquisition include an FDA-approved manufacturing facility, research and development

The closing of the financing is expected to occur within five business days. HPPI will use this funding to immediately accelerate its development program, which is focused on

DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

PXS4728A is a Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor discovered by Pharmaxis that works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes. Pharmaxis has developed

The primary objectives of COPD treatment are to enable patients to effectively manage their disease, improve their health status (measured by the St George’s Respiratory Questionnaire (SGRQ)) and